Zhilin Luo
Papers
1
Total Citations
53
H-Index
1
About
Zhilin Luo is a prominent clinical researcher in thoracic oncology, whose work centers on neoadjuvant immunotherapy for resectable non-small cell lung cancer (NSCLC). Dr. Luo’s major contribution is pioneering the combination of PD-1 inhibitors with chemotherapy prior to surgery, a strategy that has significantly improved pathological complete response rates and long-term outcomes for patients. Their landmark 2021 open-label, multicenter, single-arm study, which has garnered over 53 citations, demonstrated the safety and efficacy of this approach, building on the foundational CheckMate 159 trial. This work has helped shift the standard of care toward chemo-immunotherapy neoadjuvant regimens, offering new hope for curative-intent treatment in locally advanced NSCLC. Dr. Luo’s research is widely cited in clinical guidelines and has influenced subsequent phase III trials. Their achievements include advancing personalized perioperative strategies and improving 5-year overall survival for patients with resectable disease, making them a key figure in the evolution of lung cancer treatment.
Research Focus
Key Achievements
Top Papers
- 1